UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30
Universe Pharmaceuticals INC
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jan 29, 2026
$3.76−0.17 (-4.33%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
35.3%−10.6 pts over 5 years
Operating margin
-16.3%−49.7 pts over 5 years
Net margin
-20.6%−45.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -22.4% | +663.4% | +257.2% | – | |
| Gross profit | +3.8% | +560.3% | +238.9% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 45.5% | -7226.1% | |
| Return on assets | – | – | -10.8% | |
| Current ratio | – | 2.91 | 4.07 | |
| Interest coverage | – | 82.8× | -10.1× | |
| Inventory turnover | – | – | 13.3× | |
| Capex to revenue | – | 0.2% | 1.5% | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Universe Pharmaceuticals generated $15.68B from operations and spent $519.80M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$15.68B
Used
$519.80M
Capital expenditure$519.80M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-20.6%
×Asset turnover0.53×
×Equity multiplier669.30×
=Return on equity, FY2025-7226.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -20.6% | 0.53× | 669.30× | -7226.1% |
| FY2024 | -37.9% | 0.68× | 2.43× | -62.3% |
| FY2023 | -20.4% | 638.11× | 0.00× | -20.8% |
| FY2022 | -19.7% | 0.62× | 0.00× | -0.0% |
| FY2021 | 23.6% | 0.97× | 1.46× | 33.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$3.67B
- Cash generatingOperating cash flow above zero-$5.05B
- Return on assets improvedROA up on the prior year-20916.5% → -5.4%
- Earnings backed by cashOperating cash flow above net income-$5.05B vs -$3.67B
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.54 → 4.07
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year26.37% → 35.28%
- More efficientAsset turnover rose551.82 → 0.26